Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario
نویسندگان
چکیده
PURPOSE The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions. METHODS Retrospective analysis was carried out on 3806 injections of 1761 patients that were administered with intravitreal bevacizumab injection at a tertiary eye care center in India. The injections were administered on a pro re nata basis for various indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). RESULTS The mean age of the patients was 61.8 ± 11.59 years. A total of 59.2% of the patients were men and 40.8% women. The most common indications for which the injection was administered were DME (27.5%), AMD (26%), and branch RVO (12.3%). Among the ocular side effects, endophthalmitis was seen in three eyes (0.08%), retinal breaks in none of the eyes whereas 35 eyes had a rise in intraocular pressure (IOP) >21 mmHg (0.9%). Preexisting glaucoma was present in four eyes while remaining 31 eyes did not have any history of glaucoma. IOP rise was significantly more in eyes with preexisting glaucoma as compared to nonglaucomatous eyes (P = 0.04). No systemic adverse events were noted in our study population. CONCLUSION Our study provides real-world evidence regarding the safety profile of intravitreal bevacizumab (Avastin). These data suggest that bevacizumab is a safe and economical pharmacotherapeutic agent that can be administered for a variety of ocular disorders. Analyzing the safety of bevacizumab is necessary for a developing country like India as the majority of the population cannot afford the costly ranibizumab as compared to bevacizumab for ocular healthcare.
منابع مشابه
Intravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization
We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...
متن کاملThe intravitreal Injection of bevacizumab:The review of Our Experience
Aim: Several ocular and systemic complications have been reported after the bevacizumab intravitreal injection. This study aims at reporting the main indications for the bevacizumab intravitreal injection in our center, the intravitreal injection method in this study, and the incidence of the post-injection complication, such as endophthalmitis.Methods: This study is a retrospective review of t...
متن کاملEffect of Avastin on intraocular pressure before and after intravitreal injections
Introduction: Intravitreal Avastin (bevacizumab) injection is reportedly accompanied by ocular and systemic side-effects. Our enquiry assesses whether there are any differences between intraocular pressure (IOP) in baseline and on the day after injection in patients treated for retinal disease. Methods: In this experimental study, 82 eyes with retinal diseases that had indication for anti-VEGF...
متن کاملTeratogenic Effects of Intravitreal Injection of Bevacizumab in a Pregnant Rat Model
Abstract: Title: Teratogenic Effects of Intravitreal Injection of Bevacizumab in Pregnant Rat Models Aim: To investigate teratogenic effect of intravitreal injection of bevacizumab in pregnant rat model Methods: Twenty seven female Wistar rat were inseminated. Pregnant rats were divided into 6 groups (three groups as case and three as control groups). Each case and control groups divided accord...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 65 شماره
صفحات -
تاریخ انتشار 2017